Pyruvate Treatment Attenuates Cerebral Metabolic Depression and Neuronal Loss After Experimental Traumatic Brain Injury
Affiliations
Experimental traumatic brain injury (TBI) is known to produce an acute increase in cerebral glucose utilization, followed rapidly by a generalized cerebral metabolic depression. The current studies determined effects of single or multiple treatments with sodium pyruvate (SP; 1000mg/kg, i.p.) or ethyl pyruvate (EP; 40mg/kg, i.p.) on cerebral glucose metabolism and neuronal injury in rats with unilateral controlled cortical impact (CCI) injury. In Experiment 1 a single treatment was given immediately after CCI. SP significantly improved glucose metabolism in 3 of 13 brain regions while EP improved metabolism in 7 regions compared to saline-treated controls at 24h post-injury. Both SP and EP produced equivalent and significant reductions in dead/dying neurons in cortex and hippocampus at 24h post-CCI. In Experiment 2 SP or EP were administered immediately (time 0) and at 1, 3 and 6h post-CCI. Multiple SP treatments also significantly attenuated TBI-induced reductions in cerebral glucose metabolism (in 4 brain regions) 24h post-CCI, as did multiple injections of EP (in 4 regions). The four pyruvate treatments produced significant neuroprotection in cortex and hippocampus 1day after CCI, similar to that found with a single SP or EP treatment. Thus, early administration of pyruvate compounds enhanced cerebral glucose metabolism and neuronal survival, with 40mg/kg of EP being as effective as 1000mg/kg of SP, and multiple treatments within 6h of injury did not improve upon outcomes seen following a single treatment.
Antmen F, Matpan E, Dayanc E, Savas E, Eken Y, Acar D Mol Neurobiol. 2025; .
PMID: 39904962 DOI: 10.1007/s12035-025-04719-6.
Metabolic-driven analytics of traumatic brain injury and neuroprotection by ethyl pyruvate.
Golovachev N, Siebold L, Sutton R, Ghavim S, Harris N, Bartnik-Olson B J Neuroinflammation. 2024; 21(1):294.
PMID: 39538295 PMC: 11562096. DOI: 10.1186/s12974-024-03280-8.
Smith G, Thapak P, Paydar A, Ying Z, Gomez-Pinilla F, Harris N Prog Neurobiol (Dover). 2023; 10(1).
PMID: 38037566 PMC: 10689006. DOI: 10.60124/j.pneuro.2023.10.07.
Kobayashi M, Moro N, Yoshino A, Kumagawa T, Shijo K, Maeda T Exp Ther Med. 2023; 26(2):378.
PMID: 37456165 PMC: 10347371. DOI: 10.3892/etm.2023.12077.
Advantages of pyruvate-based fluids in preclinical shock resuscitation-A narrative review.
Zhou F Front Physiol. 2022; 13:1027440.
PMID: 36505043 PMC: 9732738. DOI: 10.3389/fphys.2022.1027440.